CV Sciences, Inc. (CVSI): R&D Expense
$122.0K
Year ended 2025-12-31
$78.0K
Trailing 12 months to 2026-06-30
-26.5%
3-year compound annual growth
-47.1%
5-year compound annual growth
-21.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $122.0K | +3.4% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $118.0K | -21.9% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $151.0K | -50.8% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $307.0K | -74.1% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $1.19M | -59.7% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $2.94M | -49.9% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $5.88M | +211.8% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $1.89M | +160.4% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $724.0K | -37.5% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $1.16M | -12.2% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $1.32M | +32.1% | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $999.3K | +90.5% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $524.5K | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| uniQure N.V. (QURE) | 2025-12-31 | $140.67M | -2.2% |
Compare CVSI, PYXS, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗